- Home
- PHGE vs ICCC Comparison
PHGE vs ICCC Comparison
Compare PHGE & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- ICCC
- Stock Information
- Founded
- PHGE 2015
- ICCC 1982
- Country
- PHGE Israel
- ICCC United States
- Employees
- PHGE N/A
- ICCC N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- ICCC Health Care
- Exchange
- PHGE Nasdaq
- ICCC Nasdaq
- Market Cap
- PHGE 26.5M
- ICCC 28.0M
- IPO Year
- PHGE N/A
- ICCC 1987
- Fundamental
- Price
- PHGE $0.49
- ICCC $3.66
- Analyst Decision
- PHGE Strong Buy
- ICCC
- Analyst Count
- PHGE 2
- ICCC 0
- Target Price
- PHGE $22.50
- ICCC N/A
- AVG Volume (30 Days)
- PHGE 159.9K
- ICCC 14.5K
- Earning Date
- PHGE 11-14-2024
- ICCC 11-13-2024
- Dividend Yield
- PHGE N/A
- ICCC N/A
- EPS Growth
- PHGE N/A
- ICCC N/A
- EPS
- PHGE N/A
- ICCC N/A
- Revenue
- PHGE N/A
- ICCC $23,838,002.00
- Revenue This Year
- PHGE N/A
- ICCC N/A
- Revenue Next Year
- PHGE N/A
- ICCC N/A
- P/E Ratio
- PHGE N/A
- ICCC N/A
- Revenue Growth
- PHGE N/A
- ICCC 46.37
- 52 Week Low
- PHGE $0.49
- ICCC $3.34
- 52 Week High
- PHGE $8.55
- ICCC $5.59
- Technical
- Relative Strength Index (RSI)
- PHGE 21.78
- ICCC 54.28
- Support Level
- PHGE $0.56
- ICCC $3.40
- Resistance Level
- PHGE $0.79
- ICCC $3.64
- Average True Range (ATR)
- PHGE 0.10
- ICCC 0.16
- MACD
- PHGE -0.02
- ICCC 0.01
- Stochastic Oscillator
- PHGE 0.00
- ICCC 65.12
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.